Polymyalgia Rheumatica (PMR) is an inflammatory rheumatic disease that commonly affects individuals over 50 years of age, characterised by pain and morning stiffness of the shoulder and pelvic girdle. PMR can present as 'isolated' form or may be associated with giant cell arteritis. The progress of imaging techniques has helped in understanding different clinical patterns: subclinical vasculitis can occur in at least one-third of PMR patients, causing ischaemic complications. It is considered a polygenic disease and environmental factors may play a role in its pathogenesis, such as viral or bacterial triggers, both in the 'wide' form or assembled with adjuvants in vaccines. The response to steroid therapy is generally dramatic and side effects may occur, as well as the development of glucocorticoid resistance. The optimisation of therapy may require steroid-sparing agents as well as modified-release prednisone as 'nighttime' replacement therapy.

Soriano, A., Landolfi, R., Manna, R., Polymyalgia rheumatica in 2011, <<BAILLIERE'S BEST PRACTICE & RESEARCH: CLINICAL RHEUMATOLOGY>>, 2012; 26 (1): 91-104. [doi:10.1016/j.berh.2012.01.007] [http://hdl.handle.net/10807/33810]

Polymyalgia rheumatica in 2011

Soriano, Alessandra;Landolfi, Raffaele;Manna, Raffaele
2012

Abstract

Polymyalgia Rheumatica (PMR) is an inflammatory rheumatic disease that commonly affects individuals over 50 years of age, characterised by pain and morning stiffness of the shoulder and pelvic girdle. PMR can present as 'isolated' form or may be associated with giant cell arteritis. The progress of imaging techniques has helped in understanding different clinical patterns: subclinical vasculitis can occur in at least one-third of PMR patients, causing ischaemic complications. It is considered a polygenic disease and environmental factors may play a role in its pathogenesis, such as viral or bacterial triggers, both in the 'wide' form or assembled with adjuvants in vaccines. The response to steroid therapy is generally dramatic and side effects may occur, as well as the development of glucocorticoid resistance. The optimisation of therapy may require steroid-sparing agents as well as modified-release prednisone as 'nighttime' replacement therapy.
2012
Inglese
Soriano, A., Landolfi, R., Manna, R., Polymyalgia rheumatica in 2011, <<BAILLIERE'S BEST PRACTICE & RESEARCH: CLINICAL RHEUMATOLOGY>>, 2012; 26 (1): 91-104. [doi:10.1016/j.berh.2012.01.007] [http://hdl.handle.net/10807/33810]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/33810
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 19
social impact